AVXL AVXL

Anavex Life Sciences Stock Price

10.80
0.00 (0.0%)
10.80
Volume 10
Bid Price 9.65
Ask Price 11.20
News -
Day High

Low
7.13

52 Week Range

High
23.73

Day Low
Company Name Stock Ticker Symbol Market Type
Anavex Life Sciences Corporation AVXL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 10.80 04:00:00
Open Price Low Price High Price Close Price Prev Close
10.80
Trades Volume Avg Volume 52 Week Range
1 10 - 7.13 - 23.73
Last Trade Time Type Quantity Stock Price Currency
04:53:06 10 $ 10.80 USD

Period:

Draw Mode:

Anavex Life Sciences Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 836.02M 77.41M 75.25M $ - $ - -0.53 -20.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 250.00k 13.10%

more financials information »

Anavex Life Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AVXL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week10.5611.86510.3311.10809,8100.242.27%
1 Month11.9113.3899.6511.16853,873-1.11-9.32%
3 Months8.9813.3897.3610.04912,0171.8220.27%
6 Months11.6113.397.1310.45930,713-0.81-6.98%
1 Year19.421123.737.1313.84963,707-8.62-44.39%
3 Years2.3431.502.2012.031,302,6578.46361.54%
5 Years3.4231.501.2510.62936,8877.38215.79%

Anavex Life Sciences Description

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.


Your Recent History
NASDAQ
AVXL
Anavex Lif..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now